Transcription factors Sp1 and Sp4 regulate TRPV1 gene expression in rat sensory neurons by Chu, Catherine et al.
RESEARCH Open Access
Transcription factors Sp1 and Sp4 regulate TRPV1
gene expression in rat sensory neurons
Catherine Chu
†, Kathryn Zavala
†, Atefeh Fahimi, Jessica Lee, Qing Xue, Helge Eilers and Mark A Schumacher
*
Abstract
Background: The capsaicin receptor, transient receptor potential vanilloid type -1 (TRPV1) directs complex roles in
signal transduction including the detection of noxious stimuli arising from cellular injury and inflammation. Under
pathophysiologic conditions, TRPV1 mRNA and receptor protein expression are elevated in dorsal root ganglion (DRG)
neurons for weeks to months and is associated with hyperalgesia. Building on our previous isolation of a promoter
system for the rat TRPV1 gene, we investigated the proximal TRPV1 P2-promoter by first identifying candidate Sp1-like
transcription factors bound in vivo to the P2-promoter using chromatin immunoprecipitation (ChIP) assay. We then
performed deletion analysis of GC-box binding sites, and quantified promoter activity under conditions of Sp1 / Sp4
over-expression versus inhibition/knockdown. mRNA encoding Sp1, Sp4 and TRPV1 were quantified by qRT-PCR under
conditions of Sp1/Sp4 over-expression or siRNA mediated knockdown in cultured DRG neurons.
Results: Using ChIP analysis of DRG tissue, we demonstrated that Sp1 and Sp4 are bound to the candidate GC-box
site region within the endogenous TRPV1 P2-promoter. Deletion of GC-box “a” or “a+b ” within the P2- promoter
resulted in a complete loss of transcriptional activity indicating that GC-box “a” was the critical site for promoter
activation. Co-transfection of Sp1 increased P2-promoter activity in cultured DRG neurons whereas mithramycin-a,
an inhibitor of Sp1-like function, dose dependently blocked NGF and Sp1-dependent promoter activity in PC12
cells. Co-transfection of siRNA directed against Sp1 or Sp4 decreased promoter activity in DRG neurons and NGF
treated PC12 cells. Finally, electroporation of Sp1 or Sp4 cDNA into cultures of DRG neurons directed an increase in
Sp1/Sp4 mRNA and importantly an increase in TRPV1 mRNA. Conversely, combined si-RNA directed knockdown of
Sp1/Sp4 resulted in a decrease in TRPV1 mRNA.
Conclusion: Based on these studies, we now propose a model of TRPV1 expression that is dependent on Sp1-like
transcription factors with Sp4 playing a predominant role in activating TRPV1 RNA transcription in DRG neurons.
Given that increases of TRPV1 expression have been implicated in a wide range of pathophysiologic states
including persistent painful conditions, blockade of Sp1-like transcription factors represents a novel direction in
therapeutic strategies.
Background
Identification of receptors/ion channels that respond to
noxious stimuli has been at the forefront of a new under-
standing of peripheral pain transduction. A seminal find-
ing was the isolation of TRPV1 (capsaicin receptor, VR1)
[1] which functions as an integrator of multiple noxious
stimuli [2-5] and is essential for the detection of inflamma-
tory pain/hyperalgesia [6,7]. TRPV1 is not only selectively
expressed in a subset of primary afferent nociceptors, but
its expression is also dynamically regulated. Nociceptor
expression of TRPV1 mRNA and receptor protein is lost
over a period of days when target-tissue derived trophic
factors such as Nerve Growth Factor (NGF) are reduced
[8,9]. In contrast, conditions that increase trophic factors
as a result of inflammation or tissue-nerve injury result in
an increase in TRPV1 mRNA and/or receptor protein
expression [10-13]. In part, these reports suggest that a
transcription-dependent mechanism drives persistent
TRPV1 mediated pain and hyperalgesia.
To advance our understanding of how TRPV1 tran-
scription is enhanced under pathophysiologic conditions,
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system for the rat TRPV1 gene [14]. These studies
revealed that the proximal P2-promoter directed cell-
type specific activity that was positively regulated by the
trophic factor NGF [14]. Building on these observations,
we now investigate the role of regulatory sites within
the P2-promoter and attempt to identify candidate tran-
scription factors that control the activity of the P2-
promoter and apparently regulate the transcription of
TRPV1 RNA in sensory neurons. Based on transcription
factor binding studies in dorsal root ganglion (DRG),
luciferase-based transcriptional assays in cultured sen-
sory neurons and NGF treated PC12 cells and quantita-
tive measurements of mRNA encoding Sp1-like factors
a n dT R P V 1 ,w ep r o p o s eam o d e lo fT R P V 1g e n e
expression that is dependent on the action of at least
two members of the Sp1-like transcription factor family,
Sp1 and Sp4, acting at a specific GC-box binding site.
Methods
Chromatin Immunoprecipitation assay (ChIP)
Identification of Sp1-like transcription factor binding to
the TRPV1 promoter in native rat dorsal root ganglion
(DRG) chromatin was obtained using ChIP-IT
® Enzy-
matic (Active Motif, Carlsbad, CA) with the following
modifications: Whole rat DRG or enriched DRG neu-
rons were harvested on ice then dounce homogenized
ten times in an ethanol - dry ice bath followed by cross-
linking (1% formaldehyde in PBS). Goat IgG antiserum
directed against Sp1 (PEP 2), Sp3 (D-20) and Sp4 (V-20)
(Santa Cruz Biotech, Santa Cruz, CA) were used to
direct chromatin antibody pull-down at 4°C overnight
(2 μg of antisera per sample). Control goat IgG was pre-
pared from normal goat serum using a Protein A- col-
umn. Cross-linking was reversed at 65°C overnight.
DNA for PCR analysis was eluted in 50 μlo fs t e r i l e
water. Primers were designed to amplify chromatin
DNA spanning P2-promoter GC-box “a” and “b” using
MacVector
® software (Accelrys, San Diego, CA). GC-
box F (5’-TTGAGTGCCAGAGTATGCCCAG), GC-box
R( 5 ’-CACCCCAAATGGAGCAAGTG). PCR: 94°C for
3 min (94°C for 20 sec; 56°C for 30 sec; 72°C for 30 sec)
and repeated for 36 cycles; and finally terminated at
4°C. PCR products were electrophoresed through a 2%
agarose gel and visualized with ethidium bromide
staining.
Cell Culture
Prior authorization was obtained through the Institu-
tional Animal Care and Use Committee- IACUC
(UCSF) for all experiments and protocols requiring the
use of rat tissues. Primary cultures of rat neonatal DRG
neurons were isolated and maintained in media contain-
ing NGF (100 ng/ml) as previously described [14]. PC12
cells from American Type Culture Collection (ATCC,
Manassas, VA) were maintained in F-12 K (Kaighn’s
Modification, Gibco-Invitrogen Corp., Rockville, MD)
supplemented with 10% heat inactivated horse serum,
5% heat inactivated fetal bovine serum (FBS), streptomy-
cin (100 μg/ml), and penicillin (100 units/ml). HEK293
cells (ATCC) were grown in Dulbecco’s modified Eagle’s
medium (DMEM) H-21 supplemented with 10% heat
inactivated FBS, streptomycin (100 μg/ml) and penicillin
(100 units/ml) (Cell Culture Facility, UCSF).
Dual Luciferase Reporter Assay
Neonatal DRG neurons and PC12 cells were plated onto
coated 96-well plates (Nunc, Naperville, IL) as previously
described [14]. In either case, each sample was composed
of 50 μLo fO p t i - M E M
® I (Cell Culture Facility, UCSF)
combined with 0.70 ng of Lipofectamine™ 2000 (Invitro-
gen, Carlsbad, CA) and allowed to incubate for 5 minutes
at room temperature. 50 μLo fO p t i - M E M
® Iw a sa l s o
combined with a total of 0.3 μg/well of the desired pGL3-
reporter construct and/or appropriate expression
construct. Additionally, the reference renilla luciferase
reporter plasmid, pRL-SV40 was included at 0.05 μg/
well. The Lipofectamine™ 2000 and DNA solutions were
then combined following the manufacturer’s recommen-
dations (Invitrogen, Carlsbad, CA). Overall, transfection
efficiency was < 5% in primary neonatal DRG neurons
[14]. When indicated, PC12 cells were cultured in the
presence of NGF (100 ng/ml) after transfection. Follow-
ing 48 hours of culture, cell lysates were prepared
according to the manufacturer’s recommendations of the
Dual Luciferase Reporter Assay System
® (Promega,
Madison, WI). Both firefly and renilla luciferase products
were measured in a MicroLumatPlus
® LB96V microplate
luminometer using Winglow
® software (Perkin-Elmer
Berthold, Wellesley, MA). Firefly luciferase activity was
normalized to renilla luciferase activity as a relative ratio
resulting in a “Relative Luciferase Activity”, which repre-
sents the transcriptional activity directed by a particular
luciferase reporter construct. In experiments where mul-
tiple expression plasmids were required, empty control
plasmid was used to maintain an equivalent DNA con-
centration between transfected samples.
Plasmid Constructs and siRNA
Luciferase reporter plasmids pGL3-E (empty) and pGL3-
0.4 kb containing TRPV1 P2-promoter were previously
described [14]. Co-expression of Sp1-like transcription
factors was accomplished through the transfection of
pN3-Sp1, pN3-Sp3, pN3-Sp4 and pN3-Empty, a gift from
Prof. G. Suske (Marburg, Germany) [15]. siRNA knock-
down experiments were performed through the transfec-
tion of the pBS/U6 plasmid based constructs containing
targeted short hairpin loops: siRNA scrambled (scr)
Chu et al. Molecular Pain 2011, 7:44
http://www.molecularpain.com/content/7/1/44
Page 2 of 14(gggaattaatatgcacacaggcc) siRNA-Sp1 (gggaacatcaccttgc-
tacct) nucleotides 881-901, accession no. NM_138473
(XM 028606.7) and siRNA Sp4-1: (gggctccaactttaacacctt)
nucleotides 1551-1571 accession no. NM_003112. Total
plasmid concentrations remained constant between
experimental groups through the addition of empty con-
trol plasmids. (siRNAs were a gift from G. Gill, Boston,
MA) [16].
Site-directed mutagenesis
To delete GC-box “a” and “b” (Figure 1A) residing within
the P2-promoter, we utilized the pGL3-0.4 kb luciferase
reporter plasmid as template and followed the manufac-
turer’s primer design software (Stratagene, La Jolla, CA)
[14]. Using primers: Del-a F (5’-CATCCCTGCCG-
TACGCCACGAGGACC CTCA); Del-a R (5’-TCTGTGA
GGGTCCTCGTGGCGTACGGCAGGGATG); Del-b F
(GAGGACCCTCAC AGAGGCACCGGCCACTC); Del-b
R (GAGTGGCCGGT GCCTCTGTGAGGGTCCTC),
deletion was performed according to the method
described in the QuikChange
® Site-Directed Mutagenesis
Kit (Stratagene, La Jolla, CA). All PCR was performed
using pfu Turbo (Stratagene, La Jolla, CA) by initially
denaturing the template at 95°C for 30 sec, followed by
denaturing at 95°C for 30 seconds, annealing at 60°C for 1
minute, extension at 68°C for 7 minutes, with this cycle
repeated 19 times. Original template DNA was digested by
Dpn I treatment at 37°C for 1 hour. After 1% agarose gel
analysis, desired bands were excised and isolated using the
PureLink Quick Gel Extraction Kit (Invitrogen, Carlsbad,
CA). Isolated DNA was then ligated using T4 DNA ligase
(New England Biolabs, Beverly, MA) and transformed into
XL1-Blue ‘super-competent’ cells (Stratagene, La Jolla,
CA). The resultant constructs containing GC-box dele-
tions “a” and “b” were subjected to DNA sequence analysis
and only the targeted GC-box binding sites “a”
(GGGGAGGGG) and “b” (GGGAGG) were confirmed to
be disrupted within the modified 0.4 kb reporter plasmid
(Biomolecular Resource Center DNA Sequencing Facility,
UCSF, San Francisco, CA).
Quantitative RT-PCR
Electroporation
To obtain a sufficiently high level of transfection effi-
ciency to detect gene expression changes in cultured
DRG neurons, we used the Amaxa Nucleofector II
Device with the Rat Neuron Nucleofector Kit (Lonza,
Basel, CH). For each nucleofection sample, we harvested
40 neonatal DRGs (~1.3 × 10
6 cells according to the
hemacytometer count). The manufacturer’sp r o t o c o l
(Optimized Protocol for Rat Dorsal Ganglion Neurons -
Amaxa
®, Lonza Basel CH) was followed: Samples were
transfected with 3 ug of the cDNA expression plasmids:
PN3-empty, PN3-Sp1, or PN3-Sp4 [15]; or the knock-
down plasmids: siRNA-scramble, siRNA-Sp1, or siRNA-
Sp4 #1 [16]. Each sample was transfected using program
G-013. Following electroporation, total DRG cultures
were plated with a total volume of 2 mL in 24-well plates
on 15mm coverslips pre-coated with poly-D-ornithine/
laminin (0.1 mg/ml/5 ug/ml). After a three-hour incuba-
tion period, the top 1 mL media was replaced with equal
volume of fresh media plus 100 ng/ml NGF. Transfection
by electroporation with 3 ug Monster™ GFP (Promega,
Madison, WI) showed a transfection efficiency of
approximately 30-40% in neonatal DRG neurons (data
not shown).
qPCR
Following RNA purification (TrIzol
®, Invitrogen, Carls-
bad, CA), precipitation and first strand cDNA synthesis
(First Strand
®, Stratagene, San Diego, CA), the level of
expression Sp1 and Sp4 mRNAs in rat DRG neurons in
culture were analyzed using quantitative real-time PCR
performed on the StepOnePlus Real-Time PCR system
(Applied Biosystems, Carlsbad, CA). Two experimental
Inp Sp1Sp4 IgG  Pr
++ +
GC box region
0.4kb P2
ab
(-203) (-50)
.50
1.0
kb
Figure 1 Transcription factors Sp1 and Sp4 are bound in vivo
to the GC-box region of P2-promoter in DRG chromatin.
Composite ethidium bromide-stained agarose gel showing evidence
of PCR amplified products directed by oligodeoxynucleotide primers
spanning TRPV1 GC-box “a” and “b” (top) using template DNA
provided as: control input chromatin DNA without
immunoprecipitation (Inp), chromatin immunoprecipitated with
antisera against transcription factors (Sp1) or (Sp4), chromatin
immunoprecipitated with non-immune (IgG), absence of chromatin
template - primers only (Pr). Plus sign (+) denotes successful
amplification of expected PCR product (arrow). There was no
evidence in vivo of Sp3 binding (not shown). Each lane represents 1
of at least 3 independent ChIP assays. Molecular size ladder: kilobase
(kb).
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the DRGs: siRNA-directed knockdown of Sp1 or Sp4
and over-expression of Sp1 or Sp4 through transfection
with Sp1 or Sp4 cDNA. All PCR reactions were per-
formed using 10 μlo fT a q M a n
® Fast Universal Master
Mix 2x (Applied Biosystems, Carlsbad, CA), 2 μl5 0n g /
μlc D N A ,1μl of forward and reverse primers, and
water to reach the final volume of 20 μl/rxn. PCR was
carried out using inventoried primers specific for rat
G6PDH from Applied Biosystems (ABI), Carlsbad, CA:
(Cat# Rn00566576_ml), Sp1 (Cat# Rn00561953_ml) and
Sp4 (Cat# Rn00562717_ml), human Sp1 (Cat#
Hs00916521_ml) and Sp4 (Cat# Hs00162095_ml), and
custom designed primers for rat TRPV1 Forward: CAA
GGC ACT TGC TCC ATT TG; Reverse: TCT GTG
GCC CAA TTT CGA; Probe: CCT GCA CCT AGC
TGG. Each sample was run as a single-plex reaction sys-
tem along with a negative control (template: water) for
each primer being tested, all samples were run in tripli-
cate. The mRNA expression levels of the genes analyzed
were represented as RelativeQ u a n t i t i e s( R Q )u s i n gt h e
comparative CT method (RQ = 2
-ΔΔCt). First, CT
(threshold cycle) values for each sample and target gene
were obtained from real-time PCR analysis with the Ste-
pOne
® Software (Applied Biosystems, Carlsbad, CA). CT
values of each gene were then normalized with respect
to the housekeeping gene (G6PDH), using the equation
where ΔΔCT =( C T, Target -C T, G6PDH) Sample -( C T, Target
-C T, G6PDH) [17]. The reference CT values were derived
from the control (empty vector/scrambled) samples. RQ
values of all other treated samples with the same target
gene are compared to the control reference values.
Statistics
Relative luciferase activity was expressed as the mean of
three independent experiments each done in at least tri-
plicate measures, +/- SEM. Mean values between groups
were compared using ANOVA with Bonferroni post-hoc
test (Prism 5.0, GraphPad). P values less than 0.05 were
considered to show a significant difference. Differences
in mRNA expression levels between non-treated control
DRGs and Sp1 or Sp4 over-expession and siRNA knock-
downs respectively, were analyzed by two-tailed
unpaired t-test with the GraphPad Prism software
(GraphPad Software, La Jolla, CA).
Results
Sp1 and Sp4 are bound in vivo to the GC-box region of
TRPV1 P2-promoter
Search for TRPV1 genomic control elements capable of
responding to inflammatory mediators revealed no clas-
sical response elements within the P2- promoter region
[14]. A search for alternative regulatory sites revealed
tandem GC-box sites 5’ to the P2 transcriptional start
site (Figure 1, top). We have termed these two GC-box
regions as: GC-box ‘a’ (GGGGAGGGGC) and GC-box
‘b’ (GGGAGGCCGGCC) (GenBank: DQ015702). Since
Sp1-like transcription factors are known to bind to GC-
box sites and activate promoter regions in an NGF-
dependent manner [18-21], we first determined if any of
the most well studied Sp1-like transcription factors
could be expressed in rat DRG by performing a RT-PCR
survey of mRNA for factors Sp1-4. mRNA encoding
transcription factors Sp1, Sp3 and Sp4 but not Sp2 were
identified in rat DRG (data not shown). To determine
which of these Sp1-like transcription factors were
expressed as protein in DRG and subsequently bound to
the endogenous TRPV1 promoter region spanning GC-
box “a” and “b”, we utilized chromatin immunoprecipi-
tation-ChIP analysis (Methods). ChIP provides for the in
vivo detection of candidate transcription factors bound
to a known promoter region within its native chromatin
s t r u c t u r e[ 2 2 - 2 4 ] .A l t h o u g hw ew e r eu n a b l et od e v e l o p
primer sets that individually amplified GC-box “a” ver-
sus “b” due to the inherent GC-content and secondary
structures (data not shown), it is understood that ChIP
analysis provides a superior method (when compared to
electrophoretic mobility shift assays - EMSA) to distin-
guish transcription factor binding that occurs only in
the context of the native chromatin structure. This is
especially critical given that Sp1-like factors (Sp1, Sp3,
Sp4) are reported to have identical binding affinities to
isolated GC-box binding targets when studied by EMSA
in vitro [25].
When sheared chromatin derived from intact DRGs
harvested from rats 1.5 months of age or enriched cul-
tures of neonatal DRG neurons were analyzed by ChIP
(Methods), we successfully amplified DRG chromatin
fragments using antisera directed against Sp1 or Sp4
(Figure 1). Overall, strong evidence for Sp1 (3/4 ChIPs)
and Sp4 (3/3 ChIPs) binding were observed (not all gels
shown). In contrast, evidence for Sp3 binding was much
less convincing (1/3 ChIPs) with a faint band represent-
ing the lowest levels of binding detectable amongst the
three transcription factors tested (data not shown).
When non-specific antiserum (IgG) was used for immu-
noprecipitation or when PCR amplification was per-
formed without template DNA (primers alone - Pr),
either a very faint band of smaller size was observed or
no detectable fragment was visualized. Nevertheless,
taken together ChIP analysis of rat DRG demonstrates
transcription factors Sp1 and Sp4 binding to a region
spanning GC boxes “a” and “b” within the P2-promoter.
We then sought to understand what functional conse-
quence Sp1-like factors have on TRPV1 promoter
activity.
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promoter
To establish a functional link between candidate GC-
box sites and P2-promoter activation, we examined the
effect of their individual deletion on P2-promoter activa-
tion in cultured DRG neurons and on NGF-dependent
promoter activity in cultured PC12 cells. As shown in
Figure 2A, when the luciferase reporter construct 0.4 kb
containing P2-promoter was transfected into cultured
DRG neurons and luciferase activity was measured
48 hours later (Methods), a robust increase in transcrip-
tional activity was observed when compared with the
empty vector control. Following the selective deletion of
GC-box “a”, P2-associated promoter activity directed by
the 0.4 kb reporter was completely lost. When GC-box
“b” was deleted but GC-box “a” remained intact, there
was a small decrease that did not reach significance. As
shown in Figure 2B, when identical experiments were
conducted in an established model of NGF action -
PC12 cells, we observed the previously reported NGF-
dependent increase in P2-promoter activity following
NGF treatment [14]. However, we also observed the loss
of NGF-dependent promoter activity with the deletion
of GC-box “a” and a small decrease in NGF dependent
activity with deletion of GC-box b that did not reach
significance. When both GC-box “a+b” were deleted, the
lowest observed level of promoter activity was obtained.
These experiments suggest that GC-box “a”, is essential
for P2-promoter activation in DRG neurons as well as
NGF-dependent transcription in PC12 cells. In contrast,
GC-box “b”,m a yh a v eam o d u l a t o r yr o l ei nD R Gn e u -
rons given that its loss is associated with a trend to
diminish promoter activity in DRG neurons.
The complete loss of promoter activity with deletion
of GC-boxes “a+b” suggests that within the P2-promo-
ter, no additional (cryptic) regulatory sites capable of
promoter activation exist beyond GC-box “a&b ”.
Given the evidence that transcription factor Sp1 is
bound to the P2-promoter (Figure 1), we then repeated
this series of experiments under conditions of Sp1 over-
expression. As shown in Figure 2A, co-transfection of
Sp1-cDNA with the P2-promoter construct 0.4 kb direc-
ted an increase in promoter activity. However, deletion
of GC-box “a”, or GC-box “a+b ”, again resulted in a
complete loss of promoter activity whereas deletion of
GC-box “b” did not show significant change in promoter
activity. Similar results were observed in parallel experi-
ments conducted in NGF treated PC12 cells (Figure 2B).
An identical series of experiments was completed, now
including conditions of Sp4 over-expression instead of
Sp1 over-expression in cultured DRG neurons and NGF
treated PC12 cells (Figure 3A,B). Although there was a
trend for increased promoter activity under conditions
of Sp4 over-expression in NGF treated PC12 cells, it did
not reach significance. As previously observed under
conditions of Sp1 over-expression, loss of promoter
activity following deletion of GC-box “a” or GC-box “a
+b ” was not reversed by Sp4. Interestingly, deletion of
GC-box “b” in this series was now associated with a sta-
tistically significant decrease in promoter activity in cul-
tured DRG neurons and NGF treated PC12 cells.
Sp1 and Sp3 increase TRPV1 P2-promoter activity in
cultured DRG neurons
Given evidence of Sp1, Sp4 and possibly small amounts
of Sp3 - binding to the GC-box region, we then sought
to determine what effect the over-expression of these
Sp1-like factors would have on P2-promoter (0.4 kb) -
directed promoter activity in cultured DRG neurons. As
shown in Figure 4, we again observed the expected
increase in promoter activity following transfection of
the 0.4 kb construct [14]. Co-transfection of expression
plasmids encoding Sp1 or Sp3 expression plasmids with
the 0.4 kb construct directed a further increase in pro-
moter activity. On the other hand, co-transfection of the
Sp4 expression plasmid did not show a significant
increase. Interestingly, when Sp1 was paired with Sp3 or
Sp4, no increase in promoter activity was observed, as
was also observed when Sp3 was paired with Sp4. These
results suggest that transcription factor Sp1 positively
regulates TRPV1 P2-promoter activity and the presence
of other members of the Sp1-like family (Sp3, Sp4) may
serve to modulate or compete for control of transcrip-
tion at the TRPV1 gene P2-promoter.
An inhibitor of Sp1-like transcription factors dose-
dependently blocks NGF and Sp1- dependent TRPV1
promoter activity in PC12 cells
T of u r t h e re s t a b l i s ht h er o l eo fS p 1 - l i k et r a n s c r i p t i o n
factors in the regulation of TRPV1 promoter activation,
we then asked whether a known inhibitor of Sp1 func-
tion could disrupt P2-promoter activity in a model of
NGF-dependent TRPV1 transcription. As previously
observed [14], NGF increased P2-promoter activity in
PC12 cells (Figure 5, 0.4 kb black bars); however,
mithramycin-a, an inhibitor of Sp1 function [26-29]
dose-dependently blocked the NGF-induced promoter
activity. Importantly, mithramycin-a also dose-depen-
dently blocked Sp1-dependent increases in P2-promoter
activity (Figure 5). Similar results were observed for Sp3
(data not shown). Attempts to perform identical experi-
ments in neonatal DRG neurons were unsuccessful due
to mithramycin-a associated toxicity and the require-
ment of NGF to sustain viability of neonatal DRG neu-
rons, not seen with PC12 cells. Although the inhibitory
effect of mithramycin-a does not preclude disruption of
other Sp1-like member binding to GC-box binding sites,
it does support the idea that in part NGF- dependent
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Figure 2 GC-box “a” is essential for TRPV1 P2-promoter activation in DRG neurons and NGF-treated PC12 cells.C o m p a r i s o no fP 2 -
promoter activity in DRG neurons + NGF (A) or +/- NGF-treated PC12 cells (B) directed by: empty pGL3 reporter plasmid (pGL-E); control
reporter plasmid (0.4 kb); 0.4 kb reporter with deletion of GC-box “a” (Del-a); 0.4 kb reporter with deletion of GC-box “b” (Del-b) or deletion of
both GC-box “a&b ”. Deletion of GC-box “a” resulted in a complete loss of promoter activity when compared with the (0.4 kb) P2-promoter
control in DRG neurons and NGF treated PC12 cells. Deletion of GC-box “b” directed a trend to decrease promoter activity in DRG neurons and
NGF treated PC12 cells. Concurrent loss of GC-box a & b resulted in the lowest measurable promoter activity. When identical experiments were
repeated under conditions of human Sp1 cDNA (A,B) over-expression, P2-promoter activity continued to be lost following deletion of GC-box “a”
or GC-box “a&b ”. Loss of GC-box “b” under conditions of Sp1 (A,B) over-expression showed a small decrease of P2-promoter activity that
attained significance in NGF treated PC12 cells. Diagram (left) indicates location of GC-box deletions and start site of transcription for P2-
promoter expressing firefly luciferase (Luc). Error bars SEM (n = 3) quadruplicate measures. Significant differences: ANOVA (***) p <0.001; (*)
p < 0.05.
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Figure 3 GC-box “b” modulates TRPV1 P2-promoter activity. Comparison of P2-promoter activity in DRG neurons + NGF (A) or +/- NGF-
treated PC12 cells (B) directed by: empty pGL3 reporter plasmid (pGL-E); control reporter plasmid (0.4 kb); 0.4 kb reporter with deletion of GC-
box “a” (Del-a); 0.4 kb reporter with deletion of GC-box “b” (Del-b) or deletion of both GC-box “a&b ”. When experiments were repeated under
conditions of human Sp4 cDNA over-expression (A,B), P2-promoter activity continued to be lost following deletion of GC-box “a” or GC-box a &
b. Loss of GC-box “b” under conditions of Sp4 (A,B) over-expression showed a small decrease of P2-promoter activity that was most evident in
NGF treated PC12 cells. Diagram (left) indicates location of GC-box deletions and start site of transcription for P2-promoter expressing firefly
luciferase (Luc). Error bars SEM (n = 3) quadruplicate measures. Significant differences: ANOVA (***) p < 0.001; (*) p < 0.05.
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Page 7 of 14transcription at P2-promoter is mediated by Sp1 and/or
other Sp1-like transcription factors.
siRNA directed knockdown of Sp1 decreases P2-promoter
activity in DRG neurons and NGF-dependent activity in
PC12 cells
Finally, we sought to demonstrate the dependence of
endogenous Sp1 and Sp4 transcription factors on the
activation of the P2-promoter through the use of a
siRNA knockdown strategy previously shown to decrease
Sp1 and Sp4 in primary cerebellar granule neurons [16].
Search for off-site hits matched only the Sp1 and Sp4
sequence in a BLAST search of the NCBI nucleotide
database (not shown). Although the low transfection effi-
ciency using lipofectamine (≤ 5%) in DRG neurons pre-
cluded quantitative analysis of Sp1 or Sp4 content
following siRNA treatment, the utility and fidelity of
these probes have been previously reported [16] and we
have subsequently validated the efficacy of DNA con-
structs for over-expression or siRNA knockdown at the
mRNA level following electroporation (see below). As
shown in Figure 6A, co-transfection of siRNA-Sp1 (Gift
from G. Gill) into cultured DRG neurons significantly
reduced P2-promoter activity directed by the 0.4 kb
reporter plasmid. Co-transfection of siRNA-Sp4 showed
a trend to decreased levels of promoter activity that did
not reach significance. Similar findings were observed
when promoter activity was studied in transfected PC12
cells. As shown in Figure 6B, NGF again directed an
expected increase in 0.4 kb reporter activity whereas co-
transfection of Sp1-siRNA decreased the NGF-dependent
promoter activity. Moreover, under conditions of Sp1
over-expression (Figure 6B, 0.4 kb Sp1), the additional
increase in promoter activity directed by Sp1 was signifi-
cantly reversed by co-transfection of Sp1-siRNA. In addi-
tion, co-transfection of siRNA-Sp4 also produced a
decrease in promoter activity in NGF-treated PC12 cells.
Over-expression of Sp1 or Sp4 increase endogenous
levels of TRPV1 mRNA in cultured DRG neurons
Building on our observations that Sp1 and Sp4 are
bound to the TRPV1 P2-promoter region in vivo and
regulate P2-promoter activity, we then attempted to
manipulate Sp1 or Sp4 expression in cultured DRG neu-
rons to determine their subsequent downstream effects
on changes in endogenous TRPV1 mRNA expression.
Given that our lipofectamine-based transfection of DRG
neurons and PC12 cells provide relatively small ( < 5%)
transfection efficiencies (Methods), we elected to con-
duct these experiments in cultured DRG neurons fol-
lowing electroporation (Methods) to provide greater
2 10 68 4
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Figure 4 Transcription factors Sp1 and Sp3 increase P2-
promoter activity in DRG neurons.P 2 -promoter reporter plasmid
(0.4 kb) directs an ~8 fold increase in luciferase activity when
compared with the empty reporter control (pGL-E). When construct
0.4 kb is co-transfected with a plasmid expressing Sp1, or Sp3, a
significant increase in promoter activity was observed. However, co-
transfection of Sp4 or a combination of Sp1/Sp3, Sp1/Sp4 or Sp3/
Sp4 (equal ratios) failed to increase promoter activity beyond what
was observed with the 0.4 kb alone. Error bars SEM (n = 3) triplicate
measures. Significant differences: ANOVA (**) p < 0.01, (*) p < 0.05.
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Figure 5 An inhibitor of Sp1 (mithramycin-a) dose-dependently
blocks NGF and Sp1- dependent P2-promoter activity in PC12
cells. P2-promoter reporter plasmid (0.4 kb) directs an ~2 fold
increase in luciferase activity when treated with NGF × 48 hours
[14]. Treatment with an inhibitor (mithramycin-a) of Sp1 function
that disrupts GC-box/transcription factor binding, blocked the NGF-
dependent P2-promoter activity. When the experiment was
repeated in the presence of co-transfected Sp1, the expected
increase in activity directed by Sp1 was dose-dependently inhibited
by mithramycin-a. Error bars SEM (n = 3) triplicate measures.
Significant differences: ANOVA (***) p < 0.001, (*) p < 0.05.
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Page 8 of 14transfection rates (30-40%) based on GFP staining in
viable cells at 24-48 hours (not shown). As shown in
Figure 7A, we first quantified endogenous levels of rat
Sp1 mRNA in cultured DRG neurons following transfec-
tion with the empty expression plasmid PN3. Because
no amplification of the Sp1/Sp4 genes for the reference
control sample occurs and 2
–ΔΔCt analysis cannot be uti-
lized, CT values are used instead of RQ values to com-
pare mRNA expression levels (Methods). We then
measured the resultant mRNA content of human Sp1
mRNA following either electroporation with the empty
PN3 vector versus a human Sp1/PN3 expression
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Figure 6 P2-promoter activity in DRG neurons is decreased by
Sp1-siRNA and Sp1 and Sp4 siRNA also block P2 promoter
activity in NGF treated PC12 cells. Co-transfection of Sp1-siRNA
with the 0.4 kb P2-promoter construct resulted in a significant
decrease in promoter activity when compared with co-transfection
of the scrambled (scr) siRNA control whereas Sp4-siRNA co-
transfection failed to show a decrease (A). In contrast, both Sp1-
siRNA and Sp4-siRNA co-transfection experiments showed a
significant decrease in NGF treated PC12 cells (B). Primary cultures
of NGF-treated dorsal root ganglion (DRG) neurons were transfected
with either (pGL-E) empty luciferase reporter plasmid; (0.4 kb + pBS)
Luciferase reporter containing the P2-promoter plus empty siRNA
vector pBS/U6; (0.4 kb + siRNA-Sp1) 0.4 kb plus siRNA construct
containing the Sp1 directed hairpin encoding Sp1 nucleotides 881-
901; (0.4 kb + siRNA-Sp4) 0.4 kb plus siRNA construct containing the
Sp4 directed hairpin encoding Sp4 nucleotides 1551-1571. (siRNAs
were a gift from G. Gill Lab, Tufts, Boston) [16]. The presence of the
scrambled siRNA control plasmid reduced the expected promoter
activity of the 0.4 kb reporter plasmid in DRG. Co-transfection of the
Sp1 cDNA in PC12 cells (0.4 kb + Sp1) directed a further increase in
P2-promoter activity that was significantly reversed by co-
transfection of the Sp1-siRNA construct. Error bars SEM (n = 3)
triplicate measures. Significant differences: ANOVA (*) p < 0.05; (***)
p < 0.001.
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Figure 7 Over-expression of transcription factor Sp1 and Sp4
mRNA increase endogenous TRPV1 mRNA in cultured DRG
neurons. (A) Measurement of endogenous levels of rat Sp1 mRNA
in cultured DRG neurons following transfection with empty/PN3
vector (left). Additional expression of an equivalent amount of
human form of Sp1 mRNA was achieved following transfection with
hSp1/PN3. (B) Endogenous TRPV1 mRNA levels were increased
following over-expression of hSp1 in cultured DRG neurons (**) p <
0.005. (C) Measurement of control levels of rat Sp4 mRNA in
cultured DRG neurons following transfection with empty/PN3 vector
(left). Additional expression of an equivalent amount of human form
of Sp4 mRNA was also achieved following transfection with hSp4/
PN3. (D) Endogenous TRPV1 mRNA levels increased following over-
expression of hSp4 in cultured DRG neurons (*). Error bars SEM (n =
3) triplicate measures. Two tailed unpaired t-test. Significance: (p <
0.05). Ct threshold values were derived from quantitative RT-PCR
amplification of cultured rat DRG neuron RNA - see Methods.
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Page 9 of 14plasmid (previously used in promoter activity assays)
and compared its CT value with the CT value associated
with baseline levels of the rat Sp1 or Sp4 mRNA.
Human Sp1-like transcription factors and their cog-
nate cDNAs differ slightly in nucleotide sequence, but
encode indistinguishable functional properties across
species. Therefore, we were able to independently mea-
sure and compare the additional contribution of human
Sp1 mRNA. As shown in Figure 7A, following transfec-
tion with the human Sp1 cDNA, an approximately equal
amount of human Sp1 mRNA in addition to the endo-
genous rat Sp1 mRNA was detected in cultured DRG
neurons. Therefore, following an approximate doubling
of Sp1 mRNA, we observed a significant increase in
endogenous TRPV1 mRNA (Figure 7B). In like manner,
we repeated these experiments but measured the endo-
genous expression of rat Sp4 mRNA (Figure 7C) and
subsequently human Sp4 mRNA content in cultured
DRG neurons following electroporation of the Sp4
cDNA. Again, we observed an approximate doubling of
Sp4 mRNA with a corresponding significant increase in
TRPV1 mRNA (Figure 7D).
Double knockdown of transcription factors Sp1 and Sp4
directs a decrease in TRPV1 mRNA in cultured DRG
neurons
Having observed the generally positive regulatory effects of
Sp1 and Sp4 on TRPV1 mRNA expression in cultured
DRG neurons (Figure 7), we returned to a siRNA knock-
down strategy to help confirm the relationship between
Sp1, Sp4 and TRPV1 RNA transcriptional control. As
shown in Figure 8A, following electroporation of cultured
DRG neurons with Sp1-siRNA, a significant decrease in
Sp1 mRNA was detected when compared with control
experiments conducted with a scrambled Sp1-like siRNA
control vector. However, no significant changes were
observed in concurrently measured Sp4 mRNA or TRPV1
mRNA content. When parallel experiments with siSp4 -
mediated knockdown were conducted, a decrease in Sp4
mRNA was observed. Importantly, when Sp4 mRNA
knockdown was achieved, there was evidence of a concur-
rent decrease in Sp1 and TRPV1 mRNA (Figure 8B).
Finally, given the apparent “cross-talk” between Sp1 and
Sp4 gene expression, we electroporated an equal ratio (1:1)
of siSp1 plus siSp4 and observed a significant decrease in
TRPV1 mRNA in cultured DRG neurons (Figure 8B).
Discussion
The regulation of transcription is a fundamental way that
mammalian cells restrict and adjust their gene expression
in response to changing cellular conditions such as stress
or injury. In the case of primary afferent nociceptors,
gene expression of ion channel -receptors such TRPV1
can be increased or decreased depending on changes in
the cellular environment. Recruitment of RNA polymer-
ase II for gene-specific transcription of TRPV1 DNA into
RNA is envisioned to require a unique set of transcrip-
tion factors that direct a subset of sensory neurons to
express TRPV1. Our findings reported here support the
hypothesis that the P2-promoter is a major site for the
regulation of TRPV1 RNA transcription. In addition to
being adjacent to TRPV1 transcriptional (RNA) start
sites confirmed by 5’-RACE and EST database [14], we
have also reported that the P2-promoter directs tran-
scription in a cell-type specific manner. Moreover, P2-
promoter activity is increased in DRG cultures enriched
in sensory neurons but lacking in cells such as 3T3 fibro-
blasts [14] or HEK293 cells (unpublished observations).
We now report that factors Sp1/Sp4, acting at a specific
GC-box binding site, play a critical role in controlling
TRPV1 RNA transcription in sensory neurons.
Transcription factors Sp1 and Sp4 regulate TRPV1 P2-
promoter activity
Two functionally distinct GC-box binding sites have
been identified within the P2-promoter. We propose
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Figure 8 Knock-down of transcription factors Sp1/Sp4 decrease
endogenous TRPV1 mRNA in cultured DRG neurons. (A)
Evidence of Sp1mRNA knockdown following transfection of siSp1 in
cultured DRG neurons (***) p < 0.0001 (left). Apparent changes in
Sp4 (middle) or TRPV1 mRNA (right) were not significant (ns). (B)
Transfection of siSp4 resulted in an apparent knockdown of Sp1,
Sp4 and TRPV1 mRNA. Combined knockdown of Sp1 + Sp4 using
an equal ratio (1:1) of siSp1/siSp4 resulted in the most consistent
knockdown of endogenous TRPV1 mRNA. Error bars SEM (n = 3)
triplicates measures. Two tailed unpaired t-test. Significant
differences: (*) p < 0.05; (***) p < 0.0001. RQ values of siRNA treated
DRGs are compared relative to the RQ values of scrambled controls
which represent baseline amounts of Sp1, Sp4 or TRPV1 mRNA
following transfection of a scrambled siRNA or Spx control vector,
see Methods for details.
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TRPV1 transcription primarily through binding to GC-
box “a” in the P2-promoter. Evidence to support this
hypothesis includes: Detection of Sp1 and Sp4 protein
bound to native DRG chromatin structure of the
TRPV1 P2-promoter region GC-box a + b (Figure 1);
Complete loss of promoter activity in DRG neurons and
NGF-treated PC12 cells following deletion of GC-box
“a” alone or both GC-box “a+b ” (Figure 2,3); Increased
promoter activity in DRG neurons co-transfected with
Sp1 (Figure 2A,4); Blockade of NGF/Sp1- dependent
promoter activity in PC12 cells using an inhibitor of
Sp1-like binding, mithramycin-a (Figure 5); Decreased
promoter activity in DRG neurons/NGF treated PC12
cells with siSp1 and decrease of Sp1-dependent promo-
ter activity with siSp1 and siSp4 in PC12 cells (Figure 6).
Factors Sp1/Sp4 regulate TRPV1 RNA transcription in
sensory neurons
Building on our observations of Sp1/Sp4 - dependent
changes in promoter activity, we then determined whether
manipulation of Sp1/Sp4 mRNA expression would direct
concomitant changes in endogenous levels of TRPV1
mRNA in sensory neurons. As shown in Figure 7, we
demonstrated that over-expression of Sp1/Sp4 mRNA in
cultured DRG neurons was associated with an increase in
TRPV1 mRNA. Conversely, we demonstrated a decrease
in TRPV1 mRNA in sensory neurons under conditions of
siSp4 and siSp1/Sp4 RNA knockdown (Figure 8B). Impor-
tantly, in both experimental series, changes in Sp4 were
associated with the largest change in TRPV1 mRNA con-
tent. This suggests that although both Sp1 and Sp4 are
bound to the P2-promoter site and are purported to have
similar DNA binding properties in vitro, Sp4 may provide
the dominant contribution to activate TRPV1 transcrip-
tion in sensory neurons.
The structure and function of Sp1-like transcription factors
Sp1, one of the first transcription factors to be isolated
[30], is the founding member of an expanding family of
Sp1-like/Kruppel-like transcription factors that share
common structural features such as glutamine-rich N-
terminal activation domains and C-terminal zinc-finger
DNA binding domains [31-33]. Members of this Sp1-like
family are distinguished by their ability to bind GC- and /
or GT-rich DNA regions within promoter regions and to
activate gene transcription. Sp1 is also one of the best-
characterized transcription factors [31,32]. Although Sp1
was initially considered to be ‘ubiquitously’ expressed, its
level of expression actually differs greatly (up to a 100
fold) during development and between tissue/cell types
[32,34]. A multitude of expressed genes common to all
cells have been proposed to be regulated by Sp1 by virtue
of containing GC/GT box binding sites within or
adjacent to their promoter region. However, the actual
number of genes critically dependent upon Sp1 are much
fewer, suggesting sophisticated roles in its maintenance
of differentiated cell types and tissue function. The role
of Sp1 in nociception is unstudied as null mice comple-
tely lacking Sp1 die early in embryogenesis [35], whereas,
Sp3 -/- null mice are growth-retarded and die at birth
due to respiratory failure [18,36]. Nevertheless, in addi-
tion to TRPV1, other Sp1-regulated genes may be
involved in nociception such as the NR1 promoter
[18,36], DRG-specific expression of H-Antigen [37] and
expression of 12 (S) lipoxygenase - products that have
been shown to mediate bradykinin induced TRPV1 acti-
vation [5,38].
Sp1-like factors share a high degree of homology, but
they do not appear to have merely redundant functional
attributes. Despite the ability of Sp1, 3 and 4 to bind
identical ‘GC-box’ consensus targets in vitro,am o r e
selective pattern of Sp1-like binding and transcriptional
activation is actually observed when studied in the con-
text of a complex genomic sequence, complex chroma-
tin structure or diverse cellular environments. This is
consistent with our observations that neither Sp3 nor
Sp4 appear to exhibit the same profile of expression/
activation as found for Sp1. Under control conditions,
we observed only trace amounts of endogenous Sp3
protein bound to DRG TRPV1 P2-promoter. However,
over-expression of Sp3 resulted in an increase in TRPV1
promoter activity (Figure 4). In contrast, co-expression
of Sp3 with Sp1 resulted in a reduction of Sp1-mediated
TRPV1 promoter activation. Therefore, as opposed to a
synergistic effect reported between the tandem binding
of Sp1, increased levels of Sp3 may serve a negative reg-
ulatory role in TRPV1 transcription. Such a role is con-
sistent with a previous report showing that Sp3 inhibits
the transcriptional activation of Sp1 [39].
Does transcription factor Sp4 play a unique role in
regulating nociceptor phenotype?
Sp4 (HF-1b) is distinguished from Sp1 and Sp3 by a
restrictive pattern of expression in neuronal cell types
[39,40]. Depending on the cellular context, there is also
evidence that Sp4 can function as a transcriptional acti-
vator but without the capacity to act in a synergistic
manner as exhibited by Sp1. Sp4 has also been reported
to be expressed in other sensory-neuronal systems such
as the cGMP - phosphodiesterase beta subunit that is
exclusively expressed in rod photoreceptors [41]. There
are no published reports focused on the consequence of
reduced Sp4 expression on behaviors related to periph-
eral nociception. Although Sp4 is highly expressed in sev-
eral subregions of the brain, Sp4 -/- null mice showed
only selective structural defects in the hippocampus [42].
Behavioral testing of mice with reduced levels of Sp4
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the hippocampus as well as contextual memory deficits
and sensori - motor gating abnormalities [43]. Mice mod-
ified with a deletion of the Sp4 N-terminal activation
domain appear normal at birth but the majority later
died by 1 month of age [44,45]. Importantly, Sp4 -/- null
mice appear to be predisposed to cardiac arrhythmias
leading to sudden death [46]. When Sp4 was reduced to
60% of expressed levels in neural crest derived cells (pri-
mary sensory, sympathetic and parasympathetic neu-
rons), physiologic defects in atrial and atrial-ventricular
conduction were found, despite a lack of morphological
changes in cardiac tissues [47]. This may reflect the loss
of specific ion channels and/or other elements that are
essential to signal transduction including synaptic struc-
ture and dendritic remodeling [16]. Although it remains
to be studied what affect the Sp4 null phenotype will
have on the regulation of peripheral pain transduction,
our findings here suggest Sp4 playing a critical role in the
gene expression of TRPV1 mRNA in DRG neurons.
Recruitment of Sp1-like transcription factors is dependent
on post-translational modification
In addition to a diverse pattern of tissue expression, Sp1
and Sp4 are subjected to a complex array of post-transla-
tional modifications that regulate target site (DNA) bind-
ing and/or recruitment of other transcription factors at
gene promoter sites. These modifications include glycosy-
lation, phosphorylation, acetylation and sumolyation
[16,48-50]. Post-translational modification of transcription
factors is a primary way by which extracellular signaling
events have long-term consequences on target gene
expression. For example, Sp1 was found to be a critical
downstream regulator of NR1 promoter activity in
response to NGF activation of the extracellular signal
regulated kinase -1 (ERK-1) cascade and the action of
phosphitidylinositol 3-kinase (PI3 K) [19]. It is interesting
to consider that NGF-induced activation of PI3 K has
been shown to not only translocate PI3 K to the nucleus
for transcriptional activation, but also to direct NGF-
induced sensitization of TRPV1 thermal hyperalgesia
through receptor modification and increased trafficking of
TRPV1 to the plasma membrane [51-53]. It is plausible
that such NGF dependent pathways could drive both
acute (receptor sensitization) and chronic (increased tran-
scription/translation) changes in nociceptor phenotype.
NGF has emerged as a key inflammatory mediator
directing both acute and persistent pain and hyperalge-
sia [12,13]. As previously published by us and others,
elevated concentrations of NGF drive an increase in
TRPV1 mRNA expression in cultured DRG neurons and
an increased number of TRPV1 mRNA positive DRG
neurons in vivo [54-57]. This is consistent with our ear-
lier findings that NGF stimulates P2-promoter activity
[14]. In this present study, NGF-dependent P2-promoter
activity requiring the presence of an intact GC-box “a”
(Figure 2D) is blocked by a known inhibitor of Sp1
function (Figure 4) and can be decreased by Sp1-siRNA
(Figure 5B). Taken together, these findings support the
hypothesis that Sp1, in part, mediates NGF-dependent
TRPV1 transcription. In the central nervous system,
Sp1-like transcription factors direct protective regulatory
responses under cellular stress and injury [58]. Sp1 has
also been shown to direct the expression of NGF depen-
dent cell survival genes [20]. In fact, Sp1 and Sp3 are
oxidative stress-induced transcription factors in cortical
neurons that function to reduce apoptosis and positively
regulate neuronal survival [59]. However, it remains to
b es t u d i e dw h a tr o l eS p 1a n di t sr e l a t e df a m i l yo ft r a n -
scription factors play under conditions of peripheral
inflammation and nerve injury.
Conclusions
We propose an initial model of rat TRPV1 gene expression
that is dependent on factors Sp1/Sp4, with Sp4 playing a
critical role in activating TRPV1 transcription (Figure 9).
0.4kb
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P2
a b
TRPV1 P2 Promoter
Transcription Start Site
ATG
+
Sp1 Sp4
Spx
NGF
+
Figure 9 Regulation of TRPV1 transcription at the rat P2-
promoter. TRPV1 P2-promoter contains two tandem GC-box
binding sites adjacent to the start site of TRPV1 transcription (arrow).
GC-box “a” was found to be essential for transcriptional activation
and appears to be the primary regulatory site in the P2-promoter
and is co-regulated by factors Sp1 and Sp4. Depending on the
cellular environment and potential state of transcription factor
abundance/modification, this model proposes factor Sp4 playing a
dominant role in the activation of TRPV1 transcription amongst the
Sp1-like factors examined in this study. One type of transcription
factor activation may arise from the activity of exogenous products
of inflammation, such as NGF. Sp1, Sp4 and/or other members of
the Sp1-like family (Spx) may also bind to GC-box region “b”
providing additional modulation and full transcriptional activation.
Classically transcriptional regulation is dynamic and rapidly responds
to intrinsic and extrinsic changes of the cellular milieu. It is
envisioned that transcriptional control is directed by a combination
of protein modifications and/or formation of a multi-protein
transcription factor complex to attract and activate RNA polymerase
II (not shown). Differing ‘sizes’ of transcription factors represent their
relative contribution to activation of TRPV1 transcription.
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HEK293 directs no TRPV1 P2-promoter activity unless
Sp4 is co-transfected (unpublished observations). Sp4 may
also form a complex with Sp1 and/or other members of
the Sp1-like family. Recently, another factor, Sp5, has been
reported and was found to repress Sp1 target genes such as
p21 [60]. The idea that Sp5 may also participate in TRPV1
transcription is attractive because Sp5 shows a restricted
pattern of expression involving the trigeminal ganglion and
dorsal portion of the spinal cord, although its role in DRG
remains unreported [61]. Ultimately, investigating the role
of Sp4 and other Sp1-like transcription factors using trans-
genic models will help reveal their contribution to the
initiation and/or maintenance of painful hyperalgesic states
observed under conditions of tissue injury.
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